The opko app is smartphone ready, and bloodwork results can be displayed on the iphone. The ultimate goal of claros device is to have all bloodwork not just 4k uploadable to smart phones. Glucose, Hep C testing, venereal
diseases, etc.. It is possible the phone might be able to read the diagnostics card in time too, using the iphone as an analyzer. Opko uses the Iphone chip in the claros device, so compatible.
stock up slightly on the news, lol. Frost buys, Shorts BUY, looking good. Great when both shorts and longs are buying together.
Not a part of the short thesis but a glance at ownership, and the short interest is revealing. If they are showing 22.5% short, double that to 45%. Of the non insider shares which cannot be short ( Roughly 50% owned by insiders ) the short interest becomes huge as a % of available float. Of available float ( excluding insider owned) funds own 36% and growing every Q, retail 64% and shrinking as funds grab those shares.
Point being every 3 million share COVER moves the stock 1-2 dollars, last Oct an 8 million share cover moved Opk about 4.00 in two weeks. Shorts are in trouble in an overcrowded trade, with no way out.
Google lakewood and opko. The author does a great job showing the historical acquisitions Dr. Frost has made, then makes the claim they are all worthless. Lakewood started shorting in the 4's well over two years ago and has held on to and adjusted his thinking to align with his underwater position. He averaged up for sure, and even held some LONG shares to hedge his losses. Read carefully, he distorts and lacks understanding of the drug Rayaldee completely. He equates it to an over the counter vitamin. He thinks the drug is in competition with the other drugs in the kidney dialysis arena. He is basically clueless about the drug but makes it a center point of his thesis. Those not taking the time to thoroughly research Rayaldee will take the Lakewood spew at face value. He makes claims also about Rolapitant, how little Frost paid, ignoring future royalties Opko owes, and claims the drug will fail Phase 3, It is going to the FDA next month. He also discounts the Claros device, 4k test claiming they will never go to market. Phase 3 was a success, and Opko is still working on the roll out. He glosses over the other tests in the pipeline, and dismisses the orphan drugs like hgh as meaningless too. Heck anyone of those could do a Billion in sales without Rayaldee, 4k, etc.
Current revenue grew 100% y/y to 100m, by late 2016 Opko will have 4 blood tests, Rolapitant, Rayaldee,
and top line data for hgh. Revenue will be over 1Billion., pt 28-32. No big spike in revenue, steady growth as each item comes on line, items Lakewood claims are worthless. So Bozza VS Frost-Soros, we will see who wins that one.
This is a publicly traded CO. that is OWNED by insiders!!! OWNED !!! SOROS and other BILLIONAIRES are buying, backing up the insiders. Knock KNOCK, I need you to cover now. THE END.
My last post above will prove prophetic,a breach of 12.95. It is GOING to happen, yes it is, and before EOY/2016. Knock knock, who is there, Uncle George, Dr. Frost, ummm, we need you to cover, we BOUGHT your shares.
Short interest has been in the 25-34 million from 4,5,6,7, and 8, It did grow after the Prolar deal, and I doubt many of the original 4 dollar shorts are still here except maybe Boza, who frantically averaged up. Figure most shorts are about break even in the 7-8 range if they reshorted enough in the 10-12 range. The smart ones have covered and moved on, this is dead money if short, a year to break even, not a good use of margin. Hanging out for a reward .25-.50 move, when upside is risk 5-6, umm, you pick. Next squeeze pushes this past 12.95, matter of when.
No way to know anything about what top line data does. I do think Opko can get to 1B revenue by EOY 2016, 28 months. I expect 1B revenue to equal a share price of roughly 28-32. Rayaldee data may or may not move the stock, I would be guessing at any PT. Revenue will drive price, Opko is about 100m in revenue now. Opko has several revenue contributors coming on line, and as they ramp up, the price will follow. Opko needs Rayaldee to do well to get to 1B in sales, Frost expects more.
4-5 tests to hit market calcium, vit D, 4k etc., organic pharma growth, rolapitant, rayaldee, nebulizer sales all by eoy 2016. 1B is a low bar.
Rolapitant NDA app Q3, July-Sept. 4k Europe launch and Latin America by Q4, on schedule. Opko hired 6 more 4k territory managers in past 8 weeks, 13 openings to be filled.
MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and diagnostics company, today announced that the United States Patent and Trademark Office granted OPKO a patent covering RAYALDEE™, the Company's product to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. The new patent (US Pat. No. 8,778,373) provides OPKO with additional intellectual property protection covering controlled release administration of a vitamin D compound. OPKO is on schedule to announce top-line results from the first pivotal phase 3 trial for RAYALDEE in the third quarter of 2014 and file a New Drug Application (NDA) with the FDA in the first quarter of 2015.
So third Q, July-Sept for Rayaldee, I thought mid Aug, it is on schedule with new drug filing by March 2015.
To quote Cramer:
Yes that’s how you have to approach it, this is a spec. I mentioned the GW Pharma earlier, this is like that.
Opko is like GW pharma, his words not mine.
Gwph 9.01-111.46 is the 52 week range, current price 88.
WOW thanks for bring this Cramer post back. Cramer comparing Opko to gwph is a nice endorsement, CNBC lightening round July 10, 2014 for any who want to hear it.
Thanx dead money.
by Sept 15 could be a catalyst to push opko over 12.95, we will see. Shorter term if we get over 9.50 and hold, we could visit 10-11. Uncle Soros could you help this cause, thanx.
Les not only has managed several biotech funds he is the author of Health Care Investing. Les is a highly respected authority who contributes regularly to CNBC.
Opko is going to have Phase 3 data coming within the next couple of months. Investors should be aware that they are coming. Data can go both ways. There is always that caveat.
Opko has a lot of other Drugs. It is less Binary. and less dependent on one outcome. Less risky way to Biotech.
Funny to see the shorts thumb a post reporting the facts about their co-conspirators, you know, a report on data. Guess they dislike the idea a few have taken their profit and moved on. Um, the sensible move, covering in the 8's but pushing the stock to the 9's costing their buds a few bucks. First to cover wins.
but think I saw Dec for the Novartis mek. Think approval by 2016 if the studies pan out. 7 phase 3 studies with results spread out through 2017, longer term thinks look good.
Current availability a tiny 350K, down from 600K at open. 1.2M available high point for July at AIB.